{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:42:53Z","timestamp":1767908573372,"version":"3.49.0"},"reference-count":81,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["RAAIDD"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Multidrug-resistant tuberculosis (MDR-TB) poses a persistent challenge to\nglobal health, necessitating continuous efforts to enhance treatment efficacy. Bedaquiline,\na cornerstone in MDR-TB management, presents biopharmaceutical challenges that impact\nits therapeutic potential. This review provides a comprehensive analysis of recent innovations\nin drug delivery strategies designed to optimize Bedaquiline's efficacy and improve\nMDR-TB treatment outcomes. Through a systematic examination of various delivery systems,\nincluding nanotechnology and formulation advancements, we explore their potential\nin addressing drug solubility and bioavailability challenges. Emphasizing the integration of\nQuality by Design (QbD) principles, this review aims to present a cohesive overview of\nevolving Bedaquiline delivery innovations, providing valuable insights for researchers and\nhealthcare practitioners working towards advancing MDR-TB treatment strategies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0127724344318310241018113206","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T07:10:42Z","timestamp":1730099442000},"page":"92-111","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bedaquiline Delivery Innovations: A Review on Advancing MDR-TB Treatment Strategies"],"prefix":"10.2174","volume":"20","author":[{"given":"Asad","family":"Ahmad","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Integral University, Lucknow, 226026, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juber","family":"Akhtar","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Integral University, Lucknow, 226026, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Integral University, Lucknow, 226026, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Badruddeen","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Integral University, Lucknow, 226026, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Irfan","family":"Khan","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Integral University, Lucknow, 226026, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Singh","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Integral University, Lucknow, 226026, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Islam","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Integral University, Lucknow, 226026, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"590","DOI":"10.5588\/ijtld.22.0263","volume":"26","author":"Migliori G.B.","year":"2022","unstructured":"Migliori G.B.; Tiberi S.; WHO drug-resistant TB guidelines 2022: What is new? Int J Tuberc Lung Dis  2022,26(7),590-591","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.15585\/mmwr.mm7235a4","volume":"72","author":"Groenweghe E.","year":"2023","unstructured":"Groenweghe E.; Swensson L.; Winans K.D.; Outbreak of multidrug-resistant tuberculosis \u2014 Kansas. MMWR Morb Mortal Wkly Rep  2023,72(35),957-960","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"e0270003","DOI":"10.1371\/journal.pone.0270003","volume":"17","author":"Xi Y.","year":"2022","unstructured":"Xi Y.; Zhang W.; Qiao R.J.; Tang J.; Risk factors for multidrug-resistant tuberculosis: A worldwide systematic review and meta-analysis. PLoS One  2022,17(6),e0270003","journal-title":"PLoS One"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"22361","DOI":"10.1038\/s41598-023-47094-9","volume":"13","author":"Akalu T.Y.","year":"2023","unstructured":"Akalu T.Y.; Clements A.C.A.; Wolde H.F.; Alene K.A.; Economic burden of multidrug-resistant tuberculosis on patients and households: A global systematic review and meta-analysis. Sci Rep  2023,13(1),22361","journal-title":"Sci Rep"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"e01324","DOI":"10.1128\/spectrum.01324-23","volume":"11","author":"Song Z.","year":"2023","unstructured":"Song Z.; Liu C.; He W.; Insight into the drug-resistant characteristics and genetic diversity of multidrug-resistant Mycobacterium tuberculosis in China. Microbiol Spectr  2023,11(5),e01324-e23","journal-title":"Microbiol Spectr"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e0270272","DOI":"10.1371\/journal.pone.0270272","volume":"17","author":"Molla K.A.","year":"2022","unstructured":"Molla K.A.; Reta M.A.; Ayene Y.Y.; Prevalence of multidrug-resistant tuberculosis in East Africa: A systematic review and meta-analysis. PLoS One  2022,17(6),e0270272","journal-title":"PLoS One"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"e0002319","DOI":"10.1371\/journal.pgph.0002319","volume":"3","author":"Mohamed M.A.","year":"2023","unstructured":"Mohamed M.A.; Ali O.A.; Osman A.M.; Assessment of drug-susceptible and multidrug-resistant tuberculosis (MDR-TB) in the Central Region of Somalia: A 3-year retrospective study. PLOS Glob Public Health  2023,3(9),e0002319","journal-title":"PLOS Glob Public Health"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1186\/s12879-022-07861-x","volume":"22","author":"Pai H.","year":"2022","unstructured":"Pai H.; Ndjeka N.; Mbuagbaw L.; Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: A retrospective cohort analysis. BMC Infect Dis  2022,22(1),870","journal-title":"BMC Infect Dis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3390\/antibiotics12101510","volume":"12","author":"Jahan R.N.","year":"2023","unstructured":"Jahan R.N.; Khan Z.; Akhtar M.S.; Development of Bedaquiline-Loaded SNEDDS Using quality by design (QbD) approach to improve biopharmaceutical attributes for the management of multidrug-resistant Tuberculosis (MDR-TB). Antibiotics  2023,12(10),1510","journal-title":"Antibiotics"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S0140-6736(12)61080-0","volume":"380","author":"Diacon A.H.","year":"2012","unstructured":"Diacon A.H.; Dawson R.; von Groote-Bidlingmaier F.; 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet  2012,380(9846),986-993","journal-title":"Lancet"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1313865","volume":"371","author":"Diacon A.H.","year":"2014","unstructured":"Diacon A.H.; Pym A.; Grobusch M.P.; Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med  2014,371(8),723-732","journal-title":"N Engl J Med"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.5588\/ijtld.14.0944","volume":"19","author":"Ndjeka N.","year":"2015","unstructured":"Ndjeka N.; Conradie F.; Schnippel K.; Treatment of drug-resistant Tuberculosis with bedaquiline in a high HIV prevalence setting: An interim cohort analysis. Int J Tuberc Lung Dis  2015,19,979-985","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1800544","DOI":"10.1183\/13993003.00544-2018","volume":"51","author":"Olayanju O.","year":"2018","unstructured":"Olayanju O.; Limberis J.; Esmail A.; Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. Eur Respir J  2018,51(5),1800544","journal-title":"Eur Respir J"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1164\/rccm.202107-1779OC","volume":"205","author":"Esmail A.","year":"2022","unstructured":"Esmail A.; Oelofse S.; Lombard C.; An all-oral 6-month regimen for multidrug-resistant tuberculosis: A multicenter, randomized controlled clinical trial (the next study). Am J Respir Crit Care Med  2022,205(10),1214-1227","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S2213-2600(19)30366-2","volume":"7","author":"Tweed C.D.","year":"2019","unstructured":"Tweed C.D.; Dawson R.; Burger D.A.; Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: A multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med  2019,7(12),1048-1058","journal-title":"Lancet Respir Med"},{"key":"ref=16","first-page":"S73","volume":"9","author":"Taune M","year":"2019","unstructured":"Taune M; Ustero P; Hiashiri S;  Successful implementation of bedaquiline for multidrug-resistant TB treatment in remote Papua New Guinea public health action  2019,9,S73-79","journal-title":"Successful implementation of bedaquiline for multidrug-resistant TB treatment in remote Papua New Guinea public health action"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"ciz1107","DOI":"10.1093\/cid\/ciz1107","author":"Kempker R.R.","year":"2019","unstructured":"Kempker R.R.; Mikiashvili L.; Zhao Y.; Clinical outcomes among patients with drug-resistant tuberculosis receiving bedaquiline or delamanid containing regimens. Clin Infect Dis  2019,ciz1107","journal-title":"Clin Infect Dis"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.5588\/ijtld.20.0048","volume":"24","author":"Padayatchi N.","year":"2020","unstructured":"Padayatchi N.; Bionghi N.; Osman F.; Treatment outcomes in patients with drug-resistant TB-HIV co-infection treated with bedaquiline and linezolid. Int J Tuberc Lung Dis  2020,24,1024-1031","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S2213-2600(18)30235-2","volume":"6","author":"Schnippel K.","year":"2018","unstructured":"Schnippel K.; Ndjeka N.; Maartens G.; Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: A retrospective cohort study. Lancet Respir Med  2018,6(9),699-706","journal-title":"Lancet Respir Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"754249","DOI":"10.3389\/fmicb.2021.754249","volume":"12","author":"Wu S.H.","year":"2021","unstructured":"Wu S.H.; Chan H.H.; Hsiao H.C.; Jou R.; Primary bedaquiline resistance among cases of drug-resistant tuberculosis in Taiwan. Front Microbiol  2021,12,754249","journal-title":"Front Microbiol"},{"key":"ref=21","first-page":"e0169413","volume":"12","author":"Xia H","year":"2017","unstructured":"Xia H; Zheng Y; Zhao B; Van Den Hof S; Cobelens F; Zhao Y.; Assessment of a 96-well plate assay of quantitative drug susceptibility testing for Mycobacterium Tuberculosis complex in China PLoS ONE  2017,12,e0169413"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e02919","DOI":"10.1128\/JCM.02919-20","volume":"60","author":"Kaniga K.","year":"2022","unstructured":"Kaniga K.; Hasan R.; Jou R.; Bedaquiline drug resistance emergence assessment in multidrug-resistant tuberculosis (MDR-TB): a 5-year prospective in vitro surveillance study of bedaquiline and other second-line drug susceptibility testing in MDR-TB isolates. J Clin Microbiol  2022,60(1),e02919-e02920","journal-title":"J Clin Microbiol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"105461","DOI":"10.1016\/j.jddst.2024.105461","volume":"94","author":"Pardhi V.P.","year":"2024","unstructured":"Pardhi V.P.; Pathak A.; Jain K.; Solid dispersions of bedaquiline fumarate to improve its pharmaceutical attributes: A comparative study between PEG and PVP. J Drug Deliv Sci Technol  2024,94,105461","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.2217\/nnm-2022-0132","volume":"17","author":"Pardhi V.P.","year":"2022","unstructured":"Pardhi V.P.; Suthar T.; Sharma A.; Jain K.; Bedaquiline fumarate microemulsion: Formulation optimization, rheological characterization and in vitro studies. Nanomedicine (Lond)  2022,17(21),1529-1546","journal-title":"Nanomedicine (Lond)"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"103690","DOI":"10.1016\/j.jddst.2022.103690","volume":"75","author":"Verma N.","year":"2022","unstructured":"Verma N.; Arora V.; Awasthi R.; Recent developments, challenges and future prospects in advanced drug delivery systems in the management of tuberculosis. J Drug Deliv Sci Technol  2022,75,103690","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jgar.2023.04.003","volume":"33","author":"Shang Y.","year":"2023","unstructured":"Shang Y.; Chen S.; Shi W.; Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients. J Glob Antimicrob Resist  2023,33,294-300","journal-title":"J Glob Antimicrob Resist"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.idc.2020.06.001","volume":"34","author":"Dousa K.M.","year":"2020","unstructured":"Dousa K.M.; Kurz S.G.; Bark C.M.; Bonomo R.A.; Furin J.J.; Drug-resistant tuberculosis. Infect Dis Clin North Am  2020,34(4),863-886","journal-title":"Infect Dis Clin North Am"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4081\/monaldi.2022.2231","volume":"93","author":"Desai G.","year":"2022","unstructured":"Desai G.; Purohit G.; Borana H.; Deokar K.; Yogi S.; Comparison of efficacy of bedaquiline and moxifloxacin in drug resistant pulmonary tuberculosis. A prospective observational study. Monaldi Arch Chest Dis  2022,93(1),93","journal-title":"Monaldi Arch Chest Dis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.54660\/.IJMRGE.2023.4.5.50-55","volume":"4","author":"Hoque M.","year":"2023","unstructured":"Hoque M.; Hossain M.S.; Akram T.; Das S.R.; Advancing healthcare: Exploring recent innovations in drug delivery systems. Multidiscip Res J  2023,4(5),50-55","journal-title":"Multidiscip Res J"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"104877","DOI":"10.1016\/j.jddst.2023.104877","volume":"87","author":"Wal P.","year":"2023","unstructured":"Wal P.; Wal A.; Saxena B.; Insights into the innovative approaches in fiber technology for drug delivery and pharmaceuticals. J Drug Deliv Sci Technol  2023,87,104877","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"109006","DOI":"10.1016\/j.exer.2022.109006","volume":"218","author":"Yang Y.","year":"2022","unstructured":"Yang Y.; Lockwood A.; Topical ocular drug delivery systems: Innovations for an unmet need. Exp Eye Res  2022,218,109006","journal-title":"Exp Eye Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cej.2017.12.110","volume":"340","author":"De Matteis L.","year":"2018","unstructured":"De Matteis L.; Jary D.; Luc\u00eda A.; New active formulations against M. tuberculosis: Bedaquiline encapsulation in lipid nanoparticles and chitosan nanocapsules. Chem Eng J  2018,340,181-191","journal-title":"Chem Eng J"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/B978-0-12-819985-5.00004-8","author":"Azger Dustachkeer V.N.","year":"2021","unstructured":"Azger Dustachkeer V.N.; Nirmal C.R.; Rajadas S.E.; Saadhali S.A.; Kannayan S.; Padmanaban V.P.; Nanotheranostic management of drug-resistant tuberculosis. A Mechanistic Approach to Medicines for Tuberculosis Nanotherapy  2021,149-173","journal-title":"A Mechanistic Approach to Medicines for Tuberculosis Nanotherapy"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"102349","DOI":"10.1016\/j.jddst.2021.102349","volume":"62","author":"Pardhi V.P.","year":"2021","unstructured":"Pardhi V.P.; Jain K.; Impact of binary\/ternary solid dispersion utilizing poloxamer 188 and TPGS to improve pharmaceutical attributes of bedaquiline fumarate. J Drug Deliv Sci Technol  2021,62,102349","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4103\/0976-500X.124435","volume":"5","author":"Goel D.","year":"2014","unstructured":"Goel D.; Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis. J Pharmacol Pharmacother  2014,5(1),76-78","journal-title":"J Pharmacol Pharmacother"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"106127","DOI":"10.1016\/j.mimet.2020.106127","volume":"181","author":"Dahanayake M.H.","year":"2021","unstructured":"Dahanayake M.H.; Jayasundera A.C.A.; Nano-based drug delivery optimization for tuberculosis treatment: A review. J Microbiol Methods  2021,181,106127","journal-title":"J Microbiol Methods"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6673-2-16","volume":"2","author":"Suri S.S.","year":"2007","unstructured":"Suri S.S.; Fenniri H.; Singh B.; Nanotechnology-based drug delivery systems. J Occup Med Toxicol  2007,2(1),16","journal-title":"J Occup Med Toxicol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1700033","DOI":"10.1002\/adtp.201700033","volume":"1","author":"Gold K.","year":"2018","unstructured":"Gold K.; Slay B.; Knackstedt M.; Gaharwar A.K.; Antimicrobial activity of metal and metal\u2010oxide based nanoparticles. Adv Ther (Weinh)  2018,1(3),1700033","journal-title":"Adv Ther (Weinh)"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1007\/s12034-016-1317-5","volume":"39","author":"Singh M.","year":"2016","unstructured":"Singh M.; Mallick A.K.; Banerjee M.; Kumar R.; Loss of outer membrane integrity in Gram-negative bacteria by silver nanoparticles loaded with Camellia sinensis leaf phytochemicals: Plausible mechanism of bacterial cell disintegration. Bull Mater Sci  2016,39(7),1871-1878","journal-title":"Bull Mater Sci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11274-017-2406-3","volume":"34","author":"Wypij M.","year":"2018","unstructured":"Wypij M.; Czarnecka J.; \u015awiecimska M.; Dahm H.; Rai M.; Golinska P.; Synthesis, characterization and evaluation of antimicrobial and cytotoxic activities of biogenic silver nanoparticles synthesized from Streptomyces xinghaiensis OF1 strain. World J Microbiol Biotechnol  2018,34(2),23","journal-title":"World J Microbiol Biotechnol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3390\/nano10020292","volume":"10","author":"S\u00e1nchez-L\u00f3pez E.","year":"2020","unstructured":"S\u00e1nchez-L\u00f3pez E.; Gomes D.; Esteruelas G.; Metal-based nanoparticles as antimicrobial agents: An overview. Nanomaterials  2020,10(2),292","journal-title":"Nanomaterials"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12866-019-1416-8","volume":"19","author":"Geitani R.","year":"2019","unstructured":"Geitani R.; Ayoub M.C.; Touqui L.; Karam Sarkis D.; Cationic antimicrobial peptides: Alternatives and\/or adjuvants to antibiotics active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. BMC Microbiol  2019,19(1),54","journal-title":"BMC Microbiol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/ja.2014.132","volume":"68","author":"Meng J.","year":"2015","unstructured":"Meng J.; He G.; Wang H.; Reversion of antibiotic resistance by inhibiting mecA in clinical methicillin-resistant Staphylococci by antisense phosphorothioate oligonucleotide. J Antibiot (Tokyo)  2015,68(3),158-164","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.3390\/molecules25081902","volume":"25","author":"Becskei A.","year":"2020","unstructured":"Becskei A.; Tuning up transcription factors for therapy. Molecules  2020,25(8),1902","journal-title":"Molecules"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/ma11020321","volume":"11","author":"Hibbitts A.","year":"2018","unstructured":"Hibbitts A.; O\u2019Leary C.; Emerging nanomedicine therapies to counter the rise of methicillin-resistant Staphylococcus aureus. Materials  2018,11(2),321","journal-title":"Materials"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"100405","DOI":"10.1016\/j.jctube.2023.100405","volume":"34","author":"Ur Rehman O.","year":"2024","unstructured":"Ur Rehman O.; Fatima E.; Ali A.; Akram U.; Nashwan A.; Yunus F.; Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: An updated systematic review and meta-analysis. J Clin Tuberc Other Mycobact Dis  2024,34,100405","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3109\/10837450.2014.898656","volume":"20","author":"Ferreira A.P.","year":"2015","unstructured":"Ferreira A.P.; Tobyn M.; Multivariate analysis in the pharmaceutical industry: Enabling process understanding and improvement in the PAT and QbD era. Pharm Dev Technol  2015,20(5),513-527","journal-title":"Pharm Dev Technol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/bcp.15925","volume":"90","author":"Mehta K.","year":"2024","unstructured":"Mehta K.; Guo T.; Van Der Graaf P.H.; Van Hasselt J.G.C.; Model\u2010based dose optimization framework for bedaquiline, pretomanid and linezolid for the treatment of drug\u2010resistant tuberculosis. Br J Clin Pharmacol  2024,90(2),463-474","journal-title":"Br J Clin Pharmacol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"e058606","DOI":"10.1136\/bmjopen-2021-058606","volume":"12","author":"Padmapriyadarsini C.","year":"2022","unstructured":"Padmapriyadarsini C.; Devaleenal B.; Ponnuraja C.; Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant\/non-responsive multidrug-resistant pulmonary tuberculosis: Study protocol. BMJ Open  2022,12(8),e058606","journal-title":"BMJ Open"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1093\/cid\/ciac528","volume":"76","author":"Padmapriyadarsini C.","year":"2023","unstructured":"Padmapriyadarsini C.; Vohra V.; Bhatnagar A.; Bedaquiline, delamanid, linezolid, and clofazimine for treatment of pre-extensively drug-resistant tuberculosis. Clin Infect Dis  2023,76(3),e938-e946","journal-title":"Clin Infect Dis"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"e00463","DOI":"10.1128\/AAC.00463-19","volume":"63","author":"Salinger D.H.","year":"2019","unstructured":"Salinger D.H.; Nedelman J.R.; Mendel C.; Spigelman M.; Hermann D.J.; Daily dosing for bedaquiline in patients with tuberculosis. Antimicrob Agents Chemother  2019,63(11),e00463-e19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1022090","DOI":"10.3389\/fphar.2023.1022090","volume":"14","author":"Shao G.","year":"2023","unstructured":"Shao G.; Bao Z.; Davies Forsman L.; Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients. Front Pharmacol  2023,14,1022090","journal-title":"Front Pharmacol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2174\/1874467215666220421130707","volume":"16","author":"Singh B.","year":"2023","unstructured":"Singh B.; Singh C.; Bedaquiline in drug-resistant tuberculosis: A mini-review. Curr Mol Pharmacol  2023,16(3),243-253","journal-title":"Curr Mol Pharmacol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"e28519","DOI":"10.7759\/cureus.28519","volume":"14","author":"Deshkar A.T.","year":"2022","unstructured":"Deshkar A.T.; Shirure P.A.; Deshkar A.; Shirure P.; Bedaquiline: A novel diarylquinoline for multidrug-resistant pulmonary tuberculosis. Cureus  2022,14(8),e28519","journal-title":"Cureus"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s40262-023-01217-7","volume":"62","author":"Mehta K.","year":"2023","unstructured":"Mehta K.; Guo T.; Van Der Graaf P.H.; Van Hasselt J.G.C.; Predictions of bedaquiline and pretomanid target attainment in lung lesions of tuberculosis patients using translational minimal physiologically based pharmacokinetic modeling. Clin Pharmacokinet  2023,62(3),519-532","journal-title":"Clin Pharmacokinet"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3390\/antibiotics12091389","volume":"12","author":"Tong E.","year":"2023","unstructured":"Tong E.; Wu Q.; Chen Y.; The efficacy and safety of bedaquiline in the treatment of pulmonary tuberculosis patients: A systematic review and meta-analysis. Antibiotics  2023,12(9),1389","journal-title":"Antibiotics"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"a017822","DOI":"10.1101\/cshperspect.a017822","volume":"5","author":"Sotgiu G.","year":"2015","unstructured":"Sotgiu G.; Centis R.; D\u2019ambrosio L.; Migliori G.B.; Tuberculosis treatment and drug regimens. Cold Spring Harb Perspect Med  2015,5(5),a017822-a2","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jmsacl.2024.01.001","volume":"31","author":"Bezawada V.","year":"2024","unstructured":"Bezawada V.; Mogili P.; Rao Polagani S.; Dodda S.; Bioanalysis of bedaquiline in human plasma by liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic study. J Mass Spectrom Adv Clin Lab  2024,31,27-32","journal-title":"J Mass Spectrom Adv Clin Lab"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3390\/antibiotics8040261","volume":"8","author":"Sarathy J.P.","year":"2019","unstructured":"Sarathy J.P.; Gruber G.; Dick T.; Re-understanding the mechanisms of action of the Anti-Mycobacterial drug bedaquiline. Antibiotics  2019,8(4),261","journal-title":"Antibiotics"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1080\/17512433.2016.1200462","volume":"9","author":"Nguyen T.V.A.","year":"2016","unstructured":"Nguyen T.V.A.; Cao T.B.T.; Akkerman O.W.; Tiberi S.; Vu D.H.; Alffenaar J.W.C.; Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis. Expert Rev Clin Pharmacol  2016,9(8),1025-1037","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jgar.2021.02.017","volume":"25","author":"Khoshnood S.","year":"2021","unstructured":"Khoshnood S.; Goudarzi M.; Taki E.; Bedaquiline: Current status and future perspectives. J Glob Antimicrob Resist  2021,25,48-59","journal-title":"J Glob Antimicrob Resist"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.ijid.2023.03.013","volume":"130","author":"Vanino E.","year":"2023","unstructured":"Vanino E.; Granozzi B.; Akkerman O.W.; Update of drug-resistant tuberculosis treatment guidelines: A turning point. Int J Infect Dis  2023,130(Suppl. 1),S12-S15","journal-title":"Int J Infect Dis"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"e01123","DOI":"10.1128\/aac.01123-22","volume":"67","author":"Kim J.","year":"2023","unstructured":"Kim J.; Choi J.; Kang H.; Safety, tolerability, pharmacokinetics, and metabolism of telacebec (Q203) for the treatment of tuberculosis: A randomized, placebo-controlled, multiple ascending dose phase 1B trial. Antimicrob Agents Chemother  2023,67(1),e01123-e22","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.biopha.2018.06.023","volume":"105","author":"Mirnejad R.","year":"2018","unstructured":"Mirnejad R.; Asadi A.; Khoshnood S.; Clofazimine: A useful antibiotic for drug-resistant tuberculosis. Biomed Pharmacother  2018,105,1353-1359","journal-title":"Biomed Pharmacother"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2217\/fmb-2019-0309","volume":"15","author":"Guglielmetti L.","year":"2020","unstructured":"Guglielmetti L.; Chiesi S.; Eimer J.; Bedaquiline and delamanid for drug-resistant tuberculosis: A clinician\u2019s perspective. Future Microbiol  2020,15(9),779-799","journal-title":"Future Microbiol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1601799","DOI":"10.1183\/13993003.01799-2016","volume":"49","author":"Guglielmetti L.","year":"2017","unstructured":"Guglielmetti L.; Jaspard M.; Le D\u00fb D.; Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J  2017,49(3),1601799","journal-title":"Eur Respir J"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/1060028013504087","volume":"48","author":"Chahine E.B.","year":"2014","unstructured":"Chahine E.B.; Karaoui L.R.; Mansour H.; Bedaquiline. Ann Pharmacother  2014,48(1),107-115","journal-title":"Ann Pharmacother"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2100621","DOI":"10.1183\/13993003.00621-2021","volume":"59","author":"Chesov E.","year":"2022","unstructured":"Chesov E.; Chesov D.; Maurer F.P.; Emergence of bedaquiline resistance in a high tuberculosis burden country. Eur Respir J  2022,59(3),2100621","journal-title":"Eur Respir J"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"e007490","DOI":"10.1136\/bmjgh-2021-007490","volume":"7","author":"Perrin C.","year":"2022","unstructured":"Perrin C.; Athersuch K.; Elder G.; Martin M.; Alsalhani A.; Recently developed drugs for the treatment of drug-resistant tuberculosis: A research and development case study. BMJ Glob Health  2022,7(4),e007490","journal-title":"BMJ Glob Health"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5588\/ijtld.16.0125","volume":"20","author":"Gupta R","year":"2016","unstructured":"Gupta R; Wells CD; Hittel N; Hafkin J; Geiter LJ; Delamanid in the treatment of multidrug-resistant tuberculosis. int j tuberc lung dis  2016,20,33-7","journal-title":"int j tuberc lung dis"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/QAI.0b013e3182410503","volume":"59","author":"Dooley K.E.","year":"2012","unstructured":"Dooley K.E.; Park J.G.; Swindells S.; Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS clinical trials group study A5267. J Acquir Immune Defic Syndr  2012,59(5),455-462","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1093\/jac\/dku504","volume":"70","author":"Svensson E.M.","year":"2015","unstructured":"Svensson E.M.; Murray S.; Karlsson M.O.; Dooley K.E.; Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother  2015,70(4),1106-1114","journal-title":"J Antimicrob Chemother"},{"key":"ref=73","first-page":"e00855","volume":"62","author":"Healan A.M.","year":"2017","unstructured":"Healan A.M.; Griffiss J.M.; Proskin H.M.; Impact of Rifabutin or Rifampin on bedaquiline safety, tolerability, and pharmacokinetics assessed in a randomized clinical trial with healthy adult volunteers. Antimicrob Agents Chemother  2017,62(1),e00855-e17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"Conradie F.","year":"2020","unstructured":"Conradie F.; Diacon A.H.; Ngubane N.; Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med  2020,382(10),893-902","journal-title":"N Engl J Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1473-3099(20)30770-2","volume":"21","author":"Dooley K.E.","year":"2021","unstructured":"Dooley K.E.; Rosenkranz S.L.; Conradie F.; QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis  2021,21(7),975-983","journal-title":"Lancet Infect Dis"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","volume":"387","author":"Conradie F.","year":"2022","unstructured":"Conradie F.; Bagdasaryan T.R.; Borisov S.; Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis. N Engl J Med  2022,387(9),810-823","journal-title":"N Engl J Med"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/14740338.2023.2219892","volume":"22","author":"Crisafulli S.","year":"2023","unstructured":"Crisafulli S.; Khan Z.; Karatas Y.; Tuccori M.; Trifir\u00f2 G.; An overview of methodological flaws of real-world studies investigating drug safety in the post-marketing setting. Expert Opin Drug Saf  2023,22(5),373-380","journal-title":"Expert Opin Drug Saf"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.addr.2018.04.004","volume":"128","author":"Colombo S.","year":"2018","unstructured":"Colombo S.; Beck-Broichsitter M.; B\u00f8tker J.P.; Malmsten M.; Rantanen J.; Bohr A.; Transforming nanomedicine manufacturing toward quality by design and microfluidics. Adv Drug Deliv Rev  2018,128,115-131","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.4155\/fmc.11.82","volume":"3","author":"Ginsberg A.","year":"2011","unstructured":"Ginsberg A.; The TB Alliance: Overcoming challenges to chart the future course of TB drug development. Future Med Chem  2011,3(10),1247-1252","journal-title":"Future Med Chem"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ijid.2014.12.039","volume":"32","author":"Zumla A.","year":"2015","unstructured":"Zumla A.; Petersen E.; Nyirenda T.; Chakaya J.; Tackling the tuberculosis epidemic in sub-Saharan Africa \u2013 unique opportunities arising from the second European Developing Countries Clinical Trials Partnership (EDCTP) programme 2015-2024. Int J Infect Dis  2015,32,46-49","journal-title":"Int J Infect Dis"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"e0239118","DOI":"10.1371\/journal.pone.0239118","volume":"15","author":"Gotham D.","year":"2020","unstructured":"Gotham D.; McKenna L.; Frick M.; Lessem E.; Public investments in the clinical development of bedaquiline. PLoS ONE  2020,15,e0239118","journal-title":"PLoS ONE"}],"container-title":["Recent Advances in Anti-Infective Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724344318310241018113206","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/235743\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724344318310241018113206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T13:34:11Z","timestamp":1744378451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/235743\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0127724344318310241018113206","relation":{},"ISSN":["2772-4344"],"issn-type":[{"value":"2772-4344","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}